RETRACTED: Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study
- PMID: 15465502
- DOI: 10.1016/j.amjmed.2004.05.019
RETRACTED: Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study
Retraction in
- 10.1016/j.amjmed.2004.05.019
-
Retraction notice to "Comparative Efficacy of Hormone Replacement Therapy, Etidronate, Calcitonin, Alfacalcidol, and Vitamin K in Postmenopausal Women with Osteoporosis: The Yamaguchi Osteoporosis Prevention Study" [The American Journal of Medicine 117 (2004) 549-555].Am J Med. 2025 May;138(5):918-919. doi: 10.1016/j.amjmed.2025.03.001. Am J Med. 2025. PMID: 40222753 No abstract available.
Abstract
This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of the Editor in Chief because of the stated concerns listed below. This article was accepted for publication by a previous editor and editorial board, at a time when submissions and documentation were in paper form, prior to the transition of The American Journal of Medicine to a digital submission and review process. These records are no longer extant and consequently we are unable to review the comments of the reviewers and editors involved at that time. We have attempted to contact the authors regarding these concerns and received no response. We are therefore retracting this article since the evidence presented below strongly argues for scientific misconduct. The integrity of these publications is severely compromised by wide-ranging and serious concerns about governance, ethics, authorship, implausible study conduct, implausible workload, discrepant participant numbers and treatment groups, impossible data, implausible data, implausible outcome data, and discrepant methodology.
Comment in
-
Concerns About the Integrity of the Yamaguchi Osteoporosis Prevention Study (YOPS) Report, Am J Med. 2004;117:549-555.Am J Med. 2020 Jun;133(6):e311-e314. doi: 10.1016/j.amjmed.2020.02.007. Am J Med. 2020. PMID: 32532372 No abstract available.
-
Concerns About the Integrity of Ishida Y, Kawai S. Am J Med. 2004;117:549-555: The Reply.Am J Med. 2020 Jun;133(6):e315. doi: 10.1016/j.amjmed.2020.02.003. Am J Med. 2020. PMID: 32532373 No abstract available.
Similar articles
-
RETRACTED: Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease.Am J Med. 2005 Nov;118(11):1250-5. doi: 10.1016/j.amjmed.2005.01.052. Am J Med. 2005. Retraction in: Am J Med. 2025 Jun;138(6):1046. doi: 10.1016/j.amjmed.2025.04.029. PMID: 16271909 Retracted.
-
RETRACTED: Beneficial effect of etidronate therapy in chronically hospitalized, disabled patients with stroke.J Stroke Cerebrovasc Dis. 2010 May;19(3):198-203. doi: 10.1016/j.jstrokecerebrovasdis.2009.04.006. J Stroke Cerebrovasc Dis. 2010. Retraction in: J Stroke Cerebrovasc Dis. 2019 Aug;28(8):2362. doi: 10.1016/j.jstrokecerebrovasdis.2019.03.034. PMID: 20434046 Retracted. Clinical Trial.
-
[Indications and limitations of non-hormonal treatments of osteoporosis].Rev Fr Gynecol Obstet. 1993 Jul-Sep;88(7-9):419-23. Rev Fr Gynecol Obstet. 1993. PMID: 8235256 Review. French.
-
RETRACTED: An open-label trial comparing alendronate and alphacalcidol in reducing falls and hip fractures in disabled stroke patients.J Stroke Cerebrovasc Dis. 2011 Jan-Feb;20(1):41-46. doi: 10.1016/j.jstrokecerebrovasdis.2009.10.007. Epub 2010 Jul 3. J Stroke Cerebrovasc Dis. 2011. Retraction in: J Stroke Cerebrovasc Dis. 2019 Nov;28(11):104426. doi: 10.1016/j.jstrokecerebrovasdis.2019.104426. PMID: 20598577 Retracted. Clinical Trial.
-
Medical treatment of vertebral osteoporosis.Eur Spine J. 2003 Oct;12 Suppl 2(Suppl 2):S132-41. doi: 10.1007/s00586-003-0608-x. Epub 2003 Sep 17. Eur Spine J. 2003. PMID: 13680313 Free PMC article. Review.
Cited by
-
Effects of vitamin K2 on the development of osteopenia in rats as the models of osteoporosis.Yonsei Med J. 2006 Apr 30;47(2):157-66. doi: 10.3349/ymj.2006.47.2.157. Yonsei Med J. 2006. PMID: 16642543 Free PMC article.
-
Molecular-Based Treatment Strategies for Osteoporosis: A Literature Review.Int J Mol Sci. 2019 May 24;20(10):2557. doi: 10.3390/ijms20102557. Int J Mol Sci. 2019. PMID: 31137666 Free PMC article. Review.
-
Vitamin K and Osteoporosis.Nutrients. 2020 Nov 25;12(12):3625. doi: 10.3390/nu12123625. Nutrients. 2020. PMID: 33255760 Free PMC article. Review.
-
Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03).J Bone Miner Metab. 2014 May;32(3):298-304. doi: 10.1007/s00774-013-0491-4. Epub 2013 Jul 5. J Bone Miner Metab. 2014. PMID: 23828145 Clinical Trial.
-
Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men.Cochrane Database Syst Rev. 2014 Apr 14;2014(4):CD000227. doi: 10.1002/14651858.CD000227.pub4. Cochrane Database Syst Rev. 2014. PMID: 24729336 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical